Aspen Pharmacare wins Canadian approval for generic Ozempic
The clearance follows expiry of Novo Nordisk's Canadian patent on semaglutide, opening the market to copies of the injectable.
MH
By Maren Holt · Senior Reporter, GLP-1
Jul 20 03:00 ETSource: Reuters
The wire
- 01Reuters reports Health Canada has approved Aspen Pharmacare's generic version of Ozempic, Novo Nordisk's injectable semaglutide for type 2 diabetes, after the originator's patent lapsed.
- 02Generic semaglutide entering a major market gives prescribers and payers a lower-cost branded alternative and reshapes the supply picture that has driven compounding demand.
- 03Pricing, launch timing and supply volumes were not detailed in the report; Canadian approval does not affect US patent status for semaglutide.
From the source
Read at reuters.comAspen Pharmacare wins Canada approval for generic Ozempic after Novo patent expiry